PTO Must Reconsider Medicines Co.'s Request For Angiomax Patent Extension
A federal court vacated the patent office's denial of The Medicines Company's application for patent term extension, saying it should reconsider the date of Angiomax approval.
A federal court vacated the patent office's denial of The Medicines Company's application for patent term extension, saying it should reconsider the date of Angiomax approval.